TG Therapeutics (NASDAQ:TGTX) Posts Earnings Results, Misses Expectations By $0.16 EPS

TG Therapeutics (NASDAQ:TGTX - Get Free Report) issued its quarterly earnings data on Monday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16), Zacks reports. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%.

TG Therapeutics Trading Down 4.3 %

Shares of TG Therapeutics stock opened at $43.44 on Monday. The business has a fifty day simple moving average of $38.56 and a 200-day simple moving average of $33.31. TG Therapeutics has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The firm has a market cap of $6.90 billion, a price-to-earnings ratio of -434.36 and a beta of 2.21. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

Analysts Set New Price Targets

Several research analysts have recently issued reports on TGTX shares. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.